

Thomas D Cook

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3177647/publications.pdf>

Version: 2024-02-01

20
papers

682
citations

840585

11
h-index

794469

19
g-index

21
all docs

21
docs citations

21
times ranked

946
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Stopping Trials Early Due to Harm. , 2022, 1, . | | 2 |
| 2 | Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort. International Journal of Cardiology, 2021, 326, 131-138. | 0.8 | 13 |
| 3 | Ancestral Folate Promotes Neuronal Regeneration in Serial Generations of Progeny. Molecular Neurobiology, 2020, 57, 2048-2071. | 1.9 | 8 |
| 4 | Missing data and sensitivity analysis for binary data with implications for sample size and power of randomized clinical trials. Statistics in Medicine, 2020, 39, 192-204. | 0.8 | 8 |
| 5 | Alternatives to Intention-to-Treat Analysesâ€”Reply. JAMA - Journal of the American Medical Association, 2019, 321, 2135. | 3.8 | 3 |
| 6 | Challenges of Nonâ€”Intention-to-Treat Analyses. JAMA - Journal of the American Medical Association, 2019, 321, 145. | 3.8 | 40 |
| 7 | The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with postâ€”myocardial infarction heart failure: Trial rationale and study design. American Heart Journal, 2018, 201, 141-148. | 1.2 | 22 |
| 8 | The microRNA miR-7a-5p ameliorates ischemic brain damage by repressing α -synuclein. Science Signaling, 2018, 11, . | 1.6 | 78 |
| 9 | Not All Stem Cells Are Created Equal. Circulation Research, 2018, 123, 944-946. | 2.0 | 10 |
| 10 | Guidelines for Statistical Analysis Plans. JAMA - Journal of the American Medical Association, 2017, 318, 2301. | 3.8 | 11 |
| 11 | Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the Tj ETQq1 1 0.784314 rgBJ /Overlock | 0.7 | 15 |
| 12 | Review of Draft FDA Adaptive Design Guidance. Journal of Biopharmaceutical Statistics, 2010, 20, 1132-1142. | 0.4 | 31 |
| 13 | The WIZARD Trial as a Case Study of Flexible Clinical Trial Design. Drug Information Journal, 2006, 40, 345-353. | 0.5 | 5 |
| 14 | Discussion of â€œp-Value Calculation for Multistage Phase II Cancer Clinical Trialsâ€”. Journal of Biopharmaceutical Statistics, 2006, 16, 777-780. | 0.4 | 3 |
| 15 | Analysis of Time-to-Event Data With Incomplete Event Adjudication. Journal of the American Statistical Association, 2004, 99, 1140-1152. | 1.8 | 15 |
| 16 | Methods for mid-course corrections in clinical trials with survival outcomes. Statistics in Medicine, 2003, 22, 3431-3447. | 0.8 | 12 |
| 17 | Azithromycin for the Secondary Prevention of Coronary Heart Disease Events. JAMA - Journal of the American Medical Association, 2003, 290, 1459. | 3.8 | 290 |
| 18 | P-Value Adjustment in Sequential Clinical Trials. Biometrics, 2002, 58, 1005-1011. | 0.8 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Advanced Statistics: Up with Odds Ratios! A Case for Odds Ratios When Outcomes Are Common. Academic Emergency Medicine, 2002, 9, 1430-1434. | 0.8 | 47 |
| 20 | Advanced Statistics: Up with Odds Ratios! A Case for Odds Ratios When Outcomes Are Common. Academic Emergency Medicine, 2002, 9, 1430-1434. | 0.8 | 54 |